Extreme insulin resistance in a patient with pre-existing diabetes during pregnancy: Role of U-500 insulin

Medical Journal of Australia

Volumn 190, Issue 11, 2009, Pages 650-651

  Wong, Vincent W ^a   Pape, Alexia V ^a  

^a LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; U 500 INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; CASE REPORT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; GESTATION PERIOD; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN TREATMENT; LETTER; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; BLOOD; DOSE RESPONSE; FOLLOW UP; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 68349088253     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02601.x     Document Type: Letter

References (5)

1. Langer O, Anyaegbunam A, Brustman L, et al. Pregestational diabetes: insulin requirement throughout pregnancy. Am J Obstet Gynecol 1988; 159: 616-621.
2. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28: 1240-1244. (Pubitemid 40616647)
3. Dolberg BK, Lenhard MJ. Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus. Endocr Pract 2000; 6: 34-36.
4. Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract 2006; 12: 542-544. (Pubitemid 46456042)
5. Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract 2007; 13: 721-725.